FFAR4, free fatty acid receptor 4, 338557

N. diseases: 67; N. variants: 20
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.030 Biomarker disease BEFREE In addition, GPR120 KO mice develop obesity, increased inflammation, and insulin resistance, consistent with a role for GPR120 signaling in the metabolic syndrome and diabetes mellitus. 22560206 2012
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.030 Biomarker disease BEFREE These findings suggest that redox regulation of GPR120/FFAR4 might be an important target in reducing risk of metabolic syndrome and associated diseases. 30658097 2019
Secondary malignant neoplasm of lymph node
0.030 AlteredExpression disease BEFREE The upregulation FFAR4 expression was associated with the lymph node metastasis and the prognosis. 31539131 2019
Secondary malignant neoplasm of lymph node
0.030 AlteredExpression disease BEFREE Moreover, the degree of FFAR4 expression was associated with aggressive clinicopathological characteristics, such as histological grade, perineural invasion (PNI), lymph node metastasis (LNM), advanced TNM stage and preoperative serum CA19-9 level (P< 0.05). 30248044 2018
Secondary malignant neoplasm of lymph node
0.030 AlteredExpression disease BEFREE The expression of GPR120 was significantly related with histological grade, TNM stage and lymph node metastasis. 29901155 2018
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis
0.030 Biomarker disease BEFREE Omega-3 polyunsaturated fatty acids protect human hepatoma cells from developing steatosis through FFA4 (GPR120). 29126901 2018
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis
0.030 AlteredExpression disease BEFREE After DHA treatment, the following modifications were present: i) the improvement of histo-pathological parameters such as NAFLD activity score, ballooning, and steatosis; ii) the reduction of hepatic progenitor cell activation in correlation with histo-pathological parameters; iii) the reduction of the number of inflammatory macrophages; iv) the increase of GPR120 expression in hepatocytes; v) the reduction of serine-311-phosphorylated nuclear factor kappa B (NF-κB) nuclear translocation in hepatocytes and macrophages in correlation with serum inflammatory cytokines. 24505350 2014
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis
0.030 Biomarker disease BEFREE Here we show that GPR120-deficient mice fed a high-fat diet develop obesity, glucose intolerance and fatty liver with decreased adipocyte differentiation and lipogenesis and enhanced hepatic lipogenesis. 22343897 2012
CUI: C0003850
Disease: Arteriosclerosis
Arteriosclerosis
0.020 Biomarker disease BEFREE Prolonged administration of GW9508 resulted in significant amelioration of atherogenesis, providing evidence that the strategy based on macrophage phenotype switching toward an M2-like activation state via stimulation of FFAR1/FFAR4 receptors holds promise for a new approach to the prevention or treatment of atherosclerosis. 31129318 2019
CUI: C0003850
Disease: Arteriosclerosis
Arteriosclerosis
0.020 AlteredExpression disease BEFREE In vivo activation of leukocyte GPR120/FFAR4 by PUFAs has minimal impact on atherosclerosis in LDL receptor knockout mice. 27811230 2017
CUI: C0004153
Disease: Atherosclerosis
Atherosclerosis
0.020 Biomarker disease BEFREE Prolonged administration of GW9508 resulted in significant amelioration of atherogenesis, providing evidence that the strategy based on macrophage phenotype switching toward an M2-like activation state via stimulation of FFAR1/FFAR4 receptors holds promise for a new approach to the prevention or treatment of atherosclerosis. 31129318 2019
CUI: C0004153
Disease: Atherosclerosis
Atherosclerosis
0.020 AlteredExpression disease BEFREE In vivo activation of leukocyte GPR120/FFAR4 by PUFAs has minimal impact on atherosclerosis in LDL receptor knockout mice. 27811230 2017
CUI: C0025202
Disease: melanoma
melanoma
0.020 AlteredExpression disease BEFREE GPR120 expression and tumor thickness (mm) show a statistically significant correlation in primary melanoma (P=0.011). 29570170 2018
CUI: C0025202
Disease: melanoma
melanoma
0.020 Biomarker disease BEFREE Different effects of GPR120 and GPR40 on cellular functions stimulated by 12-O-tetradecanoylphorbol-13-acetate in melanoma cells. 27163640 2016
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.020 Biomarker disease BEFREE Overall, these findings define a mechanism by which FFAR1-and FFAR4-dependent activation of Hippo pathway mediates DHA-induced apoptosis of androgen-independent prostate cancer cells, thus providing a promising therapeutic target for prostate cancer. 30366669 2018
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.020 AlteredExpression disease BEFREE In human tissue, higher expression of stromal GPR120 correlated with greater reduction in expression of CCP genes in men with prostate cancer on a high-ω-3 diet (r = -.57, P = .04). 30202902 2019
CUI: C0400966
Disease: Non-alcoholic Fatty Liver Disease
Non-alcoholic Fatty Liver Disease
0.020 AlteredExpression disease BEFREE After DHA treatment, the following modifications were present: i) the improvement of histo-pathological parameters such as NAFLD activity score, ballooning, and steatosis; ii) the reduction of hepatic progenitor cell activation in correlation with histo-pathological parameters; iii) the reduction of the number of inflammatory macrophages; iv) the increase of GPR120 expression in hepatocytes; v) the reduction of serine-311-phosphorylated nuclear factor kappa B (NF-κB) nuclear translocation in hepatocytes and macrophages in correlation with serum inflammatory cytokines. 24505350 2014
CUI: C0400966
Disease: Non-alcoholic Fatty Liver Disease
Non-alcoholic Fatty Liver Disease
0.020 GeneticVariation disease BEFREE We examined the association between NAFLD and eleven single nucleotide polymorphisms (SNPs) at genetic loci potentially associated with liver damage (GCKR, MBOAT7, GPR120), oxidative stress (SOD2), lipid metabolism (PNPLA3, TM6SF2, LPIN1, ELOVL2, FADS2, MTTP) and fibrogenesis (KLF6) in a paediatric population. 31255630 2019
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.020 Biomarker disease BEFREE Overall, these findings define a mechanism by which FFAR1-and FFAR4-dependent activation of Hippo pathway mediates DHA-induced apoptosis of androgen-independent prostate cancer cells, thus providing a promising therapeutic target for prostate cancer. 30366669 2018
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.020 AlteredExpression disease BEFREE In human tissue, higher expression of stromal GPR120 correlated with greater reduction in expression of CCP genes in men with prostate cancer on a high-ω-3 diet (r = -.57, P = .04). 30202902 2019
CUI: C0009319
Disease: Colitis
Colitis
0.010 Biomarker disease BEFREE GPR120, a potential therapeutic target for experimental colitis in IL-10 deficient mice. 28039475 2017
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.010 AlteredExpression disease BEFREE Finally, we find that GPR120 expression is positively correlated with VEGF expression and inversely correlated with the epithelial marker E-cadherin in CRC tissues. 23851494 2013
CUI: C0010346
Disease: Crohn Disease
Crohn Disease
0.010 Biomarker disease BEFREE This study was aimed at figuring out whether DHA could ameliorate the Crohn's colitis by activating GPR120 and whether GPR120 could be a potential therapeutic target for CD.16 week-old mice included in our present study were divided into three groups, WT group, IL-10 KO group and DHA group(IL-10 KO mice with DHA treatment, i.g., 35.5mg/kg/d), containing 8 mice in each group. 28039475 2017
CUI: C0015695
Disease: Fatty Liver
Fatty Liver
0.010 Biomarker disease BEFREE Here we show that GPR120-deficient mice fed a high-fat diet develop obesity, glucose intolerance and fatty liver with decreased adipocyte differentiation and lipogenesis and enhanced hepatic lipogenesis. 22343897 2012
CUI: C0018801
Disease: Heart failure
Heart failure
0.010 Biomarker disease BEFREE ω3-Polyunsaturated fatty acids for heart failure: Effects of dose on efficacy and novel signaling through free fatty acid receptor 4. 27986444 2017